Cognition Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, small-molecule therapeutics targeting age-related neurodegenerative diseases and disorders of the central nervous system (CNS) and retina. The company's scientific approach centers on targeting the sigma-2 (σ-2) receptor complex to protect neuronal synapses from toxic protein oligomers, such as beta-amyloid and alpha-synuclein, which drive the progression of diseases like Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). Its lead product candidate is zervimesine (CT1812), an orally delivered, once-daily small molecule designed to prevent synaptic binding of these toxic oligomers and rescue compromised cellular function.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following positive Phase 2 SHIMMER trial results, the company pivoted its strategic focus to prioritize advancing zervimesine (CT1812) toward a registrational program specifically for dementia with Lewy bodies (DLB) psychosis.
Expected impact: Expedites zervimesine's path to market by targeting an indication with high unmet medical need and no currently approved treatments.
Concluded the MAGNIFY clinical study for geographic atrophy secondary to dry AMD to focus resources and clinical development efforts on core neurodegenerative indications (Alzheimer's disease and DLB).
Expected impact: Reduces R&D cash burn and extends the operational runway to support late-stage trials for zervimesine.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
ACTC provides the clinical trial infrastructure and academic network of premier sites across North America to conduct the Phase 2 START study of zervimesine in early Alzheimer's disease.
Terms: Supported by an $81 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
Collaborated on the Phase 2 SHIMMER study evaluating zervimesine in mild-to-moderate dementia with Lewy bodies, helping to facilitate patient outreach and trial execution.
Terms: Supported in part by a $30 million grant from the National Institute on Aging (NIA).